Diagnostic Advances Tackling TB
- An estimated 1.6 million people died of TB in 2021.2
- Globally, an estimated 10.61 million people developed TB in 2021.
- Reduced access to TB diagnosis and treatment has resulted in reductions in the number of people provided with treatment for drug-resistant TB and an increase in TB deaths.1
- Drug-resistant TB continues to be a public health threat.
- With the impact of COVID globally estimated multidrug resistant TB/rifampicin resistant TB cases has increased from 437k in 2020 and 450k in 2021.3
The WHO treatment guidelines for isoniazid-resistant tuberculosis recommends for detection of genetic mutations associated with resistance to isoniazid (katG or inhA).4
“Without rapid testing for INH resistance, the appropriate implementation of a reliably effective regimen can be delayed..”5
To support TB surveillance, reporting and treatment, diagnostic tools must provide rapid and accurate detection of TB as well as drug susceptibility testing.
Experts Dr. Hoffman and Dr. Ismail are employing new diagnostic tools to impact TB control in Central/Eastern Europe and South Africa respectively.
They shared their experiences and outlined the WHO recommendations for TB screening, in our recent webinars, which are available for you to view now.
New tools for TB Diagnosis:
A look at the transition of the South African TB diagnostic algorithm
Dr. Farzana Ismail
Center for TB National Reference Lab National Institute for Communicable Diseases
WHO Supranational Reference Lab,
Johannesbourg, South Africa
Learning objectives:
- Recent experiences on new tools for TB diagnosis.
- A deep look at the transition of the recent South African TB diagnostic algorithm.
Advances on diagnostics of tuberculosis and management: Quantum leaps or continuous hard work
Dr. Harald Hoffmann
Medical Managing Director
SYNLAB Gauting
WHO Supranational Reference Lab,
Gauting, Germany
Learning objectives:
- Diagnostic methods for tuberculosis (TB)
- Role of Drug Susceptibility Testing (DST)
- Rational Use of Anti-TB Drugs Based on DST Results
- Advancements in TB Diagnostics and Future Considerations
An integrated portfolio of powerful diagnostic solutions for tuberculosis
We help you to gain comprehensive insights by first detecting Mycobacterium tuberculosis (MTB) and possible resistance to first-line treatment options and then, if needed, supporting physicians as they tailor the optimal treatment regimen with full phenotypic drug susceptibility testing. Better insights lead to more informed decision making and more appropriate treatment so that you can improve laboratory efficiencies and achieve a streamlined diagnostic pathway.
Ending the TB epidemic
Click the link below to watch how the BD TB solution supports you with TB Diagnosis.
Rapidly detect MTB and multidrug-resistant tuberculosis (MDR-TB) with BD MAX™ MDR-TB
PCR can accelerate TB detection and is specifically recommended by WHO for pulmonary TB testing.
BD MAX™ is a system that performs nucleic acid extraction and real-time PCR, and which is easy to use.6
In addition, the BD MAX™ MDR-TB assay has a high sensitivity and specificity for the detection of MDR-TB and the mutations for RIF and INH drug resistance, endorsed by WHO for this purpose.
